IMU Biosciences secures £11.5m in Series A funding led by Molten Ventures to expand its techbio platform
The financing round was led by Molten Ventures with backing from LifeX Ventures and private individuals.
A biotechnology company that maps the human immune system using single blood samples and artificial intelligence.
IMU Biosciences has closed an £11.5m Series A financing round led by Molten Ventures, with participation from LifeX Ventures and individual backers. The fresh capital will be deployed to advance the company platform, foster strategic partnerships, conduct large-scale immune research, and expand operations into the United States.
The London-based techbio firm couples systems-level immune profiling with an artificial intelligence platform to build a detailed human immune atlas. The technology is applied across multiple sectors including immune-oncology, cell therapy, autoimmune disorders, and transplantation to improve diagnostics and treatment responses.
From the founder
"With our technology, we’re building the world’s largest immune data assets across health and disease, which allows us to perform analyses with a level of depth and granularity that was previously unthinkable. This systems-level approach to understanding immune function enables us to look at the bigger picture rather than just focusing on individual disease-associated parameters. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run."
Adam Laing
President and Chief Scientific Officer at IMU Biosciences
Investor perspective
"IMU’s technology has the potential to transform our understanding of the immune system. Its advanced AI platform – combined with deep immune data profiling – enables unique insights into the immune system, which plays a critical role in virtually every disease. We are thrilled to lead this investment round and support IMU in their journey towards groundbreaking discoveries in healthcare."
Inga Deakin
Partner, Molten
Use of funds
- 01Continue product development
- 02Fund research and development
- 03Expand into international markets
Investors
Categories
About the company
IMU Biosciences
Mapping the human immune system through advanced blood analysis.